

23 Nov 2020 |

Quick Listen: Scrip's Five Must-Know Things

by **Ian Haydock**

Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of *Scrip's Five Must-Know Things*.

Join us in this regular podcast covering major industry events over the past week, as brought to you by *Scrip's* global team, this time for the business week ended 20 November 2020.

In this episode, we look at results and plans for coronavirus vaccines, a US product setback, PCSK9 developments, and the latest progress in NASH.

[Click here to explore this interactive content online](#) ✎

These and other Informa Pharma Intelligence podcasts are available via SoundCloud, Apple Podcasts, Google Play and TuneIn, and also via smart speakers - just make sure you have set up at least one of these platforms as your default player for podcasts and then ask for "Pharma Intelligence podcasts".

Articles mentioned in this episode:

(Also see "[Moderna Aces COVID-19 Vaccine Results With 94.5% Efficacy](#)" - Scrip, 16 Nov, 2020.)

(Also see "[Pfizer Pilots COVID-19 Immunization Plan In Four States As 'Dry Run'](#)" - Scrip, 17 Nov, 2020.)

(Also see "[*Sanofi Stunned As FDA Says No To CAD Drug Sutimlimab*](#)" - Scrip, 16 Nov, 2020.)

(Also see "[*Ionis, AstraZeneca To Use Real-World Data To Accelerate RNA-Targeting Cholesterol Drug*](#)" - Scrip, 13 Nov, 2020.)

(Also see "[*Year Of NASH Upheaval Means Incremental Data At AASLD*](#)" - Scrip, 18 Nov, 2020.)

Details of the FDA/CMS summit on 7-9 December as mentioned in the podcast can be [*found here*](#).